Rx-360 announces Mark Paxton as new CEO
Rx-360’s first CEO will lead the consortium to its next phase of growth.
Rx-360 has appointed Mark S. Paxton to the position of CEO of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of the organization since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Mark will provide leadership to a vibrant organization of 300 volunteers from over 100 institutions that are organized in 17 working groups with activities in the US, Europe, China and India.
Rx-360’s first CEO will lead the consortium and its membership in executing the Board’s Strategic Plan, expanding its membership and creating global awareness of Rx-360’s central mission: To protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain.
“I am delighted to welcome Mark to Rx-360. We have in Mark the leader that will take the consortium to its next phase of growth so that we may harness the passion of all those of us in the Industry that put the patient ahead of everything else,” says Guy Villax, Rx-360 Chair.
Mark comes to Rx-360 from the FDA where he led an international Strategic Program focused on medical product quality and supply chain security under Asia-Pacific Economic Cooperation (APEC), a multi-lateral forum of governments to promote sustainable economic growth within the Asia-Pacific region.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance